In Salt Lake City on September 11, 2025, Co-Diagnostics, Inc. declared that they conducted an in silico analysis. The company, listed as CODX on Nasdaq, specializes in molecular diagnostics and possesses a patented platform for creating molecular diagnostic tests. This analysis by Co-Diagnostics, Inc. signifies a significant step forward in their field.